Quick View
| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥1056.2B | ¥1029.4B | +2.6% |
| Operating Income | ¥55.1B | ¥56.2B | −1.9% |
| Ordinary Income | ¥54.7B | ¥53.5B | +2.2% |
| Net Income | ¥35.7B | ¥32.9B | +8.4% |
| ROE | 15.1% | 14.5% | - |
Executive Summary
FY2025 Q3 (9-month cumulative) results show revenue of 105.6B yen (YoY +2.6%), operating income of 5.5B yen (YoY -1.9%), ordinary income of 5.5B yen (YoY +2.2%), and net income attributable to owners of 3.6B yen (YoY +8.4%). The company achieved top-line growth while operating profit declined slightly, but ordinary income and net income both improved YoY, indicating a revenue up/profit mixed pattern with bottom-line improvement supported by non-operating income and tax factors.
Performance Drivers
Revenue increased 2.7B yen YoY to 105.6B yen, driven by growth across all three reporting segments. Medical segment revenue rose 3.4% YoY from 53.4B yen to 55.2B yen, with medical contracting services expanding from 47.1B yen to 49.1B yen while medical dispatching declined slightly from 5.1B yen to 4.8B yen. Elderly Care segment revenue grew 1.0% YoY from 41.9B yen to 42.3B yen, showing steady demand for nursing care services. Children segment revenue increased 6.2% YoY from 7.6B yen to 8.1B yen, marking the highest growth rate among segments. The Medical segment remains the core business, accounting for 52.3% of total revenue.
Operating income declined 1.1B yen YoY from 5.6B yen to 5.5B yen despite revenue growth, indicating margin compression. Operating margin declined to 5.2% from 5.5% YoY, a decrease of 0.3 percentage points. Gross profit margin stood at 16.4%, significantly below typical industry benchmarks, suggesting price competition or cost structure challenges. Selling, general and administrative expenses increased from 11.5B yen to 11.8B yen, growing at 2.6%, roughly matching revenue growth rate but offsetting gross profit expansion.
Ordinary income improved to 5.5B yen from 5.4B yen YoY despite lower operating income, benefiting from improved non-operating income. Non-operating income contribution was approximately 0.2B yen positive (ordinary income of 5.5B yen minus operating income of 5.5B yen). Net income grew 8.4% YoY from 3.3B yen to 3.6B yen, outpacing ordinary income growth due to lower tax burden or extraordinary items. The divergence between operating income (declining) and net income (rising) reflects non-operating and below-the-line factors supporting bottom-line performance.
This represents a revenue up/profit mixed pattern, where top-line growth was achieved across all segments but operating efficiency declined, while non-operating factors and tax effects supported net income growth.
Segment Analysis
Medical segment generated revenue of 55.2B yen and operating income of 3.1B yen, representing 52.3% of total revenue and 56.2% of total segment operating profit. This segment functions as the core business with operating margin of 5.6%, above the company average. Within Medical, contracting services accounted for 49.1B yen while dispatching services contributed 4.8B yen, with contracting showing stronger growth momentum.
Elderly Care segment recorded revenue of 42.3B yen and operating income of 2.3B yen, contributing 40.0% of revenue and 41.5% of segment operating profit. Operating margin of 5.4% was slightly below the Medical segment, reflecting potentially tighter pricing or higher cost structures in nursing care services.
Children segment achieved revenue of 8.1B yen and operating income of 0.1B yen, representing 7.7% of revenue but only 2.3% of segment operating profit. Operating margin of 1.6% was materially lower than other segments, indicating this remains a developing business with limited profitability. The segment showed highest revenue growth rate at 6.2% YoY but profitability improvement remains a challenge.
Margin differences between segments are material, with Medical and Elderly Care operating at 5-6% margins while Children operates at sub-2% margin, suggesting different competitive dynamics and cost structures across service categories.
Key Metrics
[Profitability] ROE of 15.1% substantially exceeds the company's historical levels and industry median of 8.2%, driven primarily by high financial leverage of 2.91x and strong asset turnover of 1.54x rather than net profit margin of 3.4%. Operating margin of 5.2% declined 0.3 percentage points from 5.5% YoY, indicating margin compression despite revenue growth. Net profit margin of 3.4% remains below industry median of 5.8%, reflecting the company's lower profitability structure. Gross profit margin of 16.4% is notably low, suggesting constrained pricing power or elevated cost base. [Cash Quality] Cash and deposits of 12.4B yen provide coverage of 24.8x against short-term debt, indicating extremely strong liquidity position. Operating cash flow of 5.4B yen represents 1.51x net income, confirming cash-backed earnings quality. [Investment Efficiency] Asset turnover of 1.54x significantly exceeds industry median of 0.68x, demonstrating efficient asset utilization typical of service businesses. Working capital turnover of 45-60 days range aligns with industry standards. Capital expenditure to depreciation ratio of 0.20x indicates substantial underinvestment in fixed assets, raising concerns about long-term capacity maintenance. [Financial Health] Equity ratio of 34.4% is below industry median of 59.0%, reflecting higher leverage strategy. Current ratio of 131.8% is below industry median of 213% but remains adequate for short-term obligations. Debt-to-equity ratio of 0.51x and interest coverage of 28.25x indicate manageable debt burden with strong servicing capability. Goodwill of 12.4B yen represents 52.4% of net assets, creating material impairment risk if acquired business performance deteriorates.
Cash Flow Analysis
Operating cash flow of 5.4B yen represents 1.51x net income of 3.6B yen, confirming strong cash conversion and earnings quality. The cash conversion ratio exceeds industry median of 1.31x, indicating above-average ability to convert profits into cash. Investing cash flow of negative 0.7B yen was primarily driven by capital expenditures of 0.2B yen, with investment activity remaining constrained. The capex-to-depreciation ratio of 0.20x signals significant underinvestment, with capital spending at only one-fifth of depreciation, raising sustainability concerns about asset base maintenance. Free cash flow of 4.7B yen provides substantial financial flexibility. Financing cash flow reflected dividend payments and share buyback activity, with treasury stock increasing from negative 1.4B yen to negative 2.1B yen, representing 0.7B yen of share repurchases during the period. Cash position of 12.4B yen provides coverage of 24.8x against short-term liabilities, ensuring robust liquidity. The combination of strong operating cash generation and minimal investment requirements has enabled aggressive capital returns through both dividends and buybacks, though the low investment rate may constrain long-term growth capacity.
Earnings Quality
Ordinary income of 5.5B yen versus operating income of 5.5B yen shows minimal non-operating contribution of approximately 0.02B yen, indicating core earnings primarily drive overall profitability. Non-operating income composition includes interest and dividend income as well as equity method investment gains, representing less than 1% of revenue and having negligible impact on earnings profile. The small gap between operating and ordinary income confirms that earnings quality is primarily determined by core business performance rather than financial or non-operating items. Operating cash flow of 5.4B yen exceeds net income of 3.6B yen by 1.51x, indicating healthy earnings quality with profits backed by actual cash generation. This cash conversion ratio above 1.0x and above industry median suggests no material accruals manipulation concerns. The declining operating margin despite revenue growth warrants monitoring, as it may signal underlying business model pressure. Goodwill balance of 12.4B yen representing 52.4% of net assets creates latent earnings quality risk, as any future impairment would directly impact net income without corresponding cash outflow. No impairment losses or material non-recurring items were reported in the current period.
Guidance Update
Full-year forecast projects revenue of 140.7B yen, operating income of 6.7B yen, ordinary income of 6.7B yen, and net income of 4.1B yen. Q3 cumulative progress rates are: revenue 75.0%, operating income 82.2%, ordinary income 81.9%, and net income 87.0%. Revenue progress aligns with the standard 75% benchmark for Q3, indicating on-track performance. Operating income and ordinary income show faster progress at approximately 82%, suggesting stronger-than-expected profitability in the first nine months. Net income progress of 87.0% substantially exceeds the Q3 standard of 75%, indicating front-loaded earnings or conservative full-year guidance. The company revised full-year forecasts with expected YoY changes of revenue +2.4%, operating income -4.2%, and ordinary income -0.8%, reflecting cautious outlook for operating profitability despite revenue growth expectations. The guidance implies Q4 will see lower margins than Q1-Q3 average, with operating income expected to contribute only 1.2B yen in Q4 versus 5.5B yen achieved in first nine months. This conservative Q4 outlook may reflect seasonality, planned investments, or management conservatism. Dividend forecast of 11 yen per share in the full-year guidance appears inconsistent with the disclosed interim dividend of 10 yen and expected year-end dividend of 10 yen (totaling 20 yen), requiring clarification.
Shareholder Returns
Annual dividend is maintained at 20 yen per share (interim 10 yen, year-end 10 yen), unchanged from prior year level. Based on Q3 cumulative net income of 3.6B yen and assuming full-year net income of 4.1B yen as guided, the payout ratio calculates to approximately 53.1%, representing moderate shareholder return commitment. Share buyback activity continued during the period, with treasury stock increasing from negative 1.4B yen to negative 2.1B yen, representing approximately 0.7B yen of repurchases. Free cash flow of 4.7B yen provides coverage of 2.47x against dividends, indicating strong sustainability of current dividend level. Total shareholder return combining dividends and buybacks demonstrates management's capital allocation priority toward returning cash to shareholders. The total return approach balances steady dividends with flexible buybacks, allowing capital efficiency optimization while maintaining consistent per-share payments. With operating cash flow of 5.4B yen substantially exceeding capital requirements, the company maintains financial capacity to sustain both dividend payments and opportunistic share repurchases. However, the extremely low capex-to-depreciation ratio of 0.20x suggests potential underinvestment in business infrastructure, which may eventually constrain growth and future return capacity if not addressed.
Risk Factors
Margin compression risk from low gross profit margin of 16.4% substantially below industry norms, exposing the company to operational leverage pressure if revenue growth slows or cost inflation accelerates. Personnel cost inflation in medical and elderly care sectors could further compress already thin margins, particularly given labor-intensive service model. Regulatory changes in healthcare reimbursement rates or elderly care subsidies could materially impact revenue and profitability across core segments.
Goodwill impairment risk from goodwill balance of 12.4B yen representing 52.4% of net assets, creating material downside to book value and earnings if acquired businesses underperform. Single impairment event could eliminate multiple years of accumulated earnings given current net income run-rate of approximately 4-5B yen annually.
Human capital and service quality risk in healthcare and elderly care businesses where personnel availability and quality directly determine service delivery capacity and customer satisfaction. Labor shortages in nursing and medical support fields could constrain growth, increase wage costs, or compromise service standards, impacting both revenue potential and profitability.
Industry Benchmark (Reference - Proprietary Data)
[Industry Position] (Reference - Proprietary Analysis)
The company operates in the IT and telecommunications services industry benchmark cohort. Profitability positioning shows ROE of 15.1% substantially exceeding industry median of 8.2% (2025-Q3, n=103), placing the company in the upper quartile. However, this elevated ROE is primarily driven by high financial leverage of 2.91x versus industry median of 1.66x, rather than superior operating profitability. Operating margin of 5.2% is significantly below industry median of 8.0%, positioning the company in the lower half of peers on core profitability. Net profit margin of 3.4% also trails industry median of 5.8%, confirming below-average profit generation efficiency.
Financial health indicators show equity ratio of 34.4% substantially below industry median of 59.0%, reflecting more aggressive capital structure. Current ratio of 131.8% is below industry median of 213%, though still adequate for liquidity needs. The company's higher leverage strategy amplifies ROE but increases financial risk relative to more conservatively capitalized peers.
Efficiency metrics demonstrate competitive advantages, with asset turnover of 1.54x more than double the industry median of 0.68x, reflecting superior asset utilization characteristic of service-focused business model. Revenue growth of 2.6% YoY significantly lags industry median of 10.4%, indicating slower top-line expansion. The combination of below-median profitability margins with above-median asset turnover suggests a volume-oriented strategy with constrained pricing power.
Industry: IT and Telecommunications Services (n=103 companies), Comparison period: 2025-Q3, Source: Proprietary analysis
Key Takeaways from Earnings
Strong cash generation capability despite modest profitability, with operating cash flow to net income ratio of 1.51x exceeding industry median of 1.31x and free cash flow of 4.7B yen supporting sustainable capital returns. The company demonstrates consistent ability to convert earnings into cash, enabling both dividend payments and share buybacks while maintaining strong liquidity position with cash coverage of 24.8x short-term obligations.
Structural profitability challenges reflected in operating margin of 5.2% and gross margin of 16.4%, both substantially below industry benchmarks, combined with declining margin trend (down 0.3 percentage points YoY). Revenue growth of 2.6% significantly trails industry median of 10.4%, while operating profit declined 1.9% YoY, creating a concerning divergence that suggests pricing pressure or cost structure disadvantages in core medical and elderly care segments.
Material capital allocation and asset quality concerns arising from goodwill representing 52.4% of net assets creating significant impairment risk, combined with capex-to-depreciation ratio of 0.20x indicating systematic underinvestment in business infrastructure. High financial leverage of 2.91x versus industry median of 1.66x amplifies ROE to 15.1% but increases balance sheet risk, while extremely low investment rate raises questions about long-term competitive position maintenance and growth sustainability.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.
AI Financial Analysis
Executive Summary
Solasto’s FY2026 Q3 cumulative results show modest revenue growth, a small operating-profit decline, but stronger ordinary and net income supported by non-operating and extraordinary items. Revenue increased 2.6% YoY to ¥105.62bn. Operating income declined 1.9% YoY to ¥5.51bn, leaving the operating margin at 5.2%, down approximately 20bp from 5.5% a year earlier. Gross profit rose 1.2% to ¥17.33bn, but gross margin compressed by roughly 20bp to 16.4%. SG&A expenses increased 2.8% to ¥11.82bn, slightly faster than revenue growth, creating modest negative operating leverage. Ordinary income nonetheless rose 2.2% to ¥5.47bn as net non-operating expense narrowed. Profit before tax increased 8.0% to ¥5.78bn and net income rose 8.4% to ¥3.57bn. The stronger bottom line was assisted by ¥3.09bn of extraordinary income, which exceeded the difference between pre-tax profit and ordinary income. Consequently, the improvement in net income is not fully representative of underlying operating momentum. Operating cash flow was strong at ¥5.41bn and exceeded net income by 1.51x, indicating good cash realization of reported earnings. Free cash flow was ¥4.68bn, supported by exceptionally low capital expenditure of ¥0.22bn. The annualized DuPont ROE is 20.1%, an attractive level, but it is supported materially by 2.91x financial leverage rather than a high net margin. The balance sheet remains liquid, with a 131.8% current ratio and cash of ¥12.40bn, while debt-servicing metrics are sound with debt/EBITDA of 1.81x and EBITDA interest coverage of 33.82x. However, goodwill represents 52.4% of equity, and JGAAP goodwill amortization of ¥1.23bn absorbs 18.7% of EBITDA, making acquired-business performance and impairment discipline central to the earnings outlook. Q3 progress against full-year guidance is ahead of the standard 75% seasonal benchmark for operating income, ordinary income and net income, although the company’s full-year plan still implies a weak final quarter. The key forward issue is whether growth in the Medical and Children businesses, together with improved Care profitability, can offset continuing medical-margin pressure and the recurring drag from goodwill amortization.
Profitability Analysis
The annualized 3-factor DuPont ROE of 20.1% is composed of a 3.4% net profit margin, 2.048x asset turnover and 2.91x financial leverage. Financial leverage is the principal structural contributor to ROE, since the net margin remains modest for a labor-intensive healthcare and care-services operator. Asset turnover is strong, reflecting a service-oriented business model with a relatively low working-capital and fixed-asset requirement relative to revenue, although the asset base includes substantial acquisition-related intangibles. The 3.4% net margin improved versus the prior-year period because net income grew 8.4%, faster than revenue growth of 2.6%, but this improvement was substantially supported by ¥3.09bn of extraordinary income. Operating profitability softened: operating income fell 1.9% and operating margin declined around 20bp to 5.2%. Gross margin also fell approximately 20bp to 16.4%, which is below the 20% quality-alert threshold and leaves limited room to absorb wage inflation or service-delivery cost escalation. SG&A rose 2.8%, faster than sales, indicating modest negative operating leverage. The Medical business remains the core business by segment operating-income contribution, generating ¥3.09bn of segment profit, or 56% of total segment profit. Medical revenue grew 3.4% to ¥55.21bn, but segment profit fell 8.4% to ¥3.09bn and segment margin declined from 6.3% to 5.6%. Care revenue increased 1.0% to ¥42.27bn, while segment profit rose 11.6% to ¥2.29bn; its margin expanded from 4.9% to 5.4%, demonstrating improved profitability despite limited sales growth. Children revenue increased 6.2% to ¥8.11bn, but segment profit decreased 31.9% to ¥1.26bn and margin fell from 2.4% to 1.6%. The Children segment’s combination of the highest revenue growth and the largest margin compression warrants monitoring, as it may indicate start-up, staffing or operating-cost pressure. Under JGAAP, goodwill amortization is charged through operating earnings; ¥1.23bn of amortization equals 18.7% of EBITDA and is therefore a material accounting drag versus IFRS peers. EBITDA before goodwill amortization was ¥7.83bn, equivalent to a 7.4% margin, compared with reported EBITDA of ¥6.60bn and a 6.2% margin.
Growth Assessment
Reported growth is moderate rather than broad-based at the operating-profit level. Revenue growth of 2.6% was led by the Medical business at 3.4% and the Children business at 6.2%, while Care grew only 1.0%. Within Medical, medical outsourcing revenue rose to ¥49.09bn from ¥47.15bn, while medical staffing revenue declined to ¥4.77bn from ¥5.08bn. This mix suggests that growth is being led by contracted healthcare operations rather than staffing. Care profitability improved meaningfully despite low revenue growth, which may be sustainable if operational efficiency and pricing discipline persist. Conversely, Medical and Children margin declines offset the Care improvement and resulted in a 1.9% reduction in consolidated operating income. Net-income growth should be viewed cautiously because extraordinary income of ¥3.09bn was a significant contributor to the 8.4% increase. Full-year revenue guidance is ¥140.74bn, implying Q3 cumulative progress of 75.1%, essentially in line with the standard 75% benchmark. Operating-income progress is 82.0% of the ¥6.72bn forecast, 7.0 percentage points above the standard progress rate. Ordinary-income progress is also 82.0% of the ¥6.67bn target, 7.0 percentage points ahead of the standard pace. Net-income progress is 88.1% of the ¥4.05bn forecast, 13.1 percentage points above the standard pace and therefore materially ahead of the typical seasonal benchmark. The guidance arithmetic implies Q4 revenue of ¥35.12bn, operating income of ¥1.21bn and net income of ¥0.48bn. The implied Q4 operating margin is approximately 3.4%, below the Q3 cumulative 5.2% margin, consistent with anticipated seasonal cost pressure, weaker profitability or conservatism in the unchanged plan. Full-year guidance calls for 2.4% revenue growth but a 4.2% decline in operating income, underscoring that management expects margin pressure to remain the primary earnings issue.
Financial Health
Liquidity is adequate. Current assets of ¥31.57bn exceed current liabilities of ¥23.94bn, producing working capital of ¥7.62bn and a current ratio of 131.8%. The quick ratio is also 131.8%, as the business has limited inventory exposure, and cash deposits of ¥12.40bn provide immediate liquidity. The company has ¥5.00bn of short-term loans and ¥4.78bn of current portions of long-term loans; these near-term borrowings are covered by cash, with cash equal to 24.80x short-term loans alone. The presence of ¥4.78bn of current maturities means refinancing and scheduled debt repayment remain relevant, but there is no evident near-term liquidity mismatch given cash and receivables of ¥15.99bn. Total interest-bearing debt is reported at ¥11.95bn, equal to 1.91x equity; this is elevated relative to a conservative capital structure but remains below the explicit 2.0x aggressive-leverage warning threshold. Debt/capital is 33.6%, below the 40% investment-grade reference point, and debt/EBITDA is 1.81x, below the 2.5x benchmark. Interest coverage is strong at 28.25x on EBIT and 33.82x on EBITDA, limiting sensitivity to current interest expense of ¥1.95bn on an annualized basis. Equity increased to ¥23.64bn from ¥22.68bn, and the capital adequacy ratio improved to 34.4% from 32.4%. Long-term loans declined by ¥4.71bn YoY to ¥11.45bn, indicating deleveraging. Treasury stock increased in absolute deduction by ¥0.65bn to negative ¥2.09bn, reflecting the ¥0.69bn share repurchase during the period; this supports per-share metrics but reduces balance-sheet equity and financial flexibility. Goodwill of ¥12.39bn equals 18.0% of assets and 52.4% of equity, above the 50% warning threshold. This goodwill concentration makes the equity base materially dependent on acquired businesses continuing to meet their cash-flow and profitability assumptions.
Notable B/S Changes
Treasury stock: increased in absolute deduction by ¥0.65bn to negative ¥2.09bn (-44.8% YoY) following ¥0.69bn of share repurchases; supportive for per-share metrics but reduces equity and modestly raises capital-structure sensitivity. Long-term loans: decreased ¥4.71bn (-31.1% YoY) to ¥11.45bn; this reflects debt repayment and improves long-term leverage, although current maturities of long-term loans remain ¥4.78bn. Goodwill: ¥12.39bn, equivalent to 18.0% of assets and 52.4% of equity; although the balance declined ¥1.23bn YoY through amortization, it remains a material M&A-related asset requiring continued impairment monitoring. Property, plant and equipment: decreased ¥0.46bn (-2.7% YoY) to ¥16.56bn while capex was only ¥0.22bn; alongside a 0.20x CapEx/depreciation ratio, this reinforces the need to monitor whether investment is being deferred.
Cash Flow Quality
Cash-flow quality is favorable for the nine-month cumulative period. Operating cash flow rose 40.3% YoY to ¥5.41bn, materially outpacing the 8.4% rise in net income. The OCF/net income ratio was 1.51x, well above the 0.8x concern threshold, and the negative 2.7% accruals ratio indicates cash conversion was not dependent on aggressive accrual-based earnings recognition. OCF/EBITDA was 0.82x, below the 0.9x excellent benchmark but comfortably above the 0.7x concern threshold. Operating cash flow benefited from a ¥1.36bn increase in payables and a ¥1.07bn increase in deposits received, while trade receivables increased by ¥1.01bn and therefore consumed cash. The receivables increase was broadly consistent with sales growth and does not by itself indicate a material working-capital manipulation concern, but collections should be monitored given receivables represent 23.3% of total assets. Free cash flow was ¥4.68bn, calculated after reported capital expenditure of ¥0.22bn. The resulting FCF strength is unusually high because capital expenditure was only 0.20x depreciation and amortization. This triggered both underinvestment quality alerts: CapEx/depreciation of 0.20x is far below the 0.7x threshold and may defer rather than eliminate maintenance spending needs. For a healthcare, care and children-services platform, persistently low investment could constrain facility quality, digitalization, service capacity and future organic growth. Investing cash flow was negative ¥0.72bn, including ¥0.39bn of intangible asset purchases, and does not indicate aggressive acquisition spending in the period. Financing cash flow was negative ¥6.29bn, driven principally by ¥3.71bn of long-term debt repayment, ¥1.93bn of cash dividends and ¥0.69bn of share repurchases. Cash declined ¥1.60bn to ¥12.40bn, but the decline reflects deliberate capital returns and debt reduction rather than weak operating cash generation.
Dividend Sustainability
The interim dividend was ¥11.00 per share. Based on the reported nine-month calculation, the dividend payout ratio was 29.2%, and free cash flow covered the interim dividend amount by 4.49x. The full-year dividend forecast is ¥22.00 per share, which implies a forecast dividend payout ratio of approximately 49.7% against forecast EPS of ¥44.23. This is below the 60% sustainability reference point and appears supportable from forecast earnings. Nine-month free cash flow of ¥4.68bn also provides ample coverage for the reported interim dividend commitment. Cash dividends paid were ¥1.93bn and share repurchases were ¥0.69bn; combined, these represent ¥2.63bn of cash shareholder returns. The corresponding nine-month total return ratio is approximately 73.5% of net income, which remains below the 80% sustainability reference point but is meaningfully higher than the dividend-only payout ratio. The dividend outlook is supported by strong operating cash conversion, modest debt/EBITDA and high interest coverage. However, the apparent FCF headroom is partly dependent on capital expenditure remaining exceptionally low. If the company normalizes maintenance or growth investment, FCF coverage of dividends and buybacks would narrow. Continued buybacks also increase treasury stock and reduce book equity, which can enhance per-share returns but modestly increases leverage sensitivity. Dividend sustainability is therefore sound on current data, while the durability of low-capex cash generation is the key capital-allocation issue.
Risk Assessment
Business risks include Labor-cost and staffing risk: the 20bp consolidated gross-margin decline, 70bp Medical segment-margin decline and 90bp Children segment-margin decline indicate sensitivity to wages, staffing availability and service-delivery costs., Medical-business profitability risk: the core Medical segment contributed 56% of segment profit, but its profit fell 8.4% despite 3.4% revenue growth., Children-business execution risk: revenue grew 6.2%, but segment profit declined 31.9%, reducing margin to 1.6% and suggesting a limited buffer against further cost pressure., Healthcare outsourcing and care-services demand risk: growth relies on continued outsourcing by medical institutions, public-sector policy conditions and stable demand for elder-care and childcare services., Acquisition integration and impairment risk: goodwill is ¥12.39bn, equal to 52.4% of equity, making value retention in acquired operations important..
Financial risks include Goodwill concentration risk: goodwill/equity exceeds the 50% warning threshold; underperformance of acquired businesses could result in impairment and a material reduction in equity., JGAAP amortization drag: goodwill amortization of ¥1.23bn equals 18.7% of EBITDA, materially depressing reported operating and net earnings relative to pre-amortization economics., Capital-investment risk: CapEx/depreciation of 0.20x is well below the 0.7x underinvestment threshold, potentially creating future catch-up spending requirements., Capital-return and equity-base risk: ¥0.69bn of buybacks increased treasury stock by 44.8% YoY in absolute deduction terms, reducing equity while returns remain cash-flow dependent., Receivables and collection risk: trade receivables increased ¥1.01bn YoY to ¥15.99bn and should remain aligned with revenue and collection trends..
Key concerns include Highest priority: sustaining operating margins despite wage and service-cost inflation, particularly in the Medical and Children segments., High priority: validating that goodwill-backed acquired businesses deliver sufficient cash flow to support their carrying values and recurring amortization burden., High priority: determining whether exceptionally low capex reflects efficiency or deferred maintenance and digital-investment needs., Moderate priority: reconciling the strong nine-month net-income progress with the low implied Q4 operating margin under full-year guidance., Moderate priority: maintaining disciplined shareholder returns while preserving balance-sheet capacity for debt maturities and investment needs..
Investment Implications
Key takeaways include Revenue growth remains positive at 2.6%, but operating income declined 1.9% because consolidated and core Medical margins compressed., Care segment profitability improved, partially offsetting pressure in Medical and Children operations., Net income growth of 8.4% exceeded operating performance because extraordinary income of ¥3.09bn supported pre-tax earnings., Operating cash flow is strong, with a 1.51x OCF/net income ratio and ¥4.68bn of free cash flow., Credit metrics are sound despite elevated D/E of 1.91x: debt/EBITDA is 1.81x and EBITDA interest coverage is 33.82x., Goodwill equals 52.4% of equity and JGAAP goodwill amortization equals 18.7% of EBITDA, creating a meaningful acquisition-related earnings and impairment sensitivity., The 0.20x CapEx/depreciation ratio is the main cash-flow-quality caveat because it may overstate sustainable free cash flow..
Metrics to watch include Medical segment revenue growth and segment margin, particularly the balance between outsourcing and staffing revenue., Children segment margin recovery from 1.6%., Consolidated gross margin and SG&A growth relative to revenue growth., Q4 operating-income delivery relative to the ¥1.21bn implied by full-year guidance., Trade receivables growth and operating cash flow conversion., CapEx/depreciation normalization and spending on facilities, systems and digital capabilities., Goodwill balance, goodwill amortization and any impairment indicators., Net debt, debt/EBITDA, scheduled current debt maturities and shareholder-return cash outflows..
Regarding relative positioning, Solasto combines attractive annualized ROE of 20.1%, solid cash conversion and conservative credit coverage with relatively low underlying operating margins. Its reported ROE is stronger than its 3.4% net margin alone would imply because it is supported by high asset turnover and 2.91x financial leverage. Relative to businesses with lower acquisition intensity, the company carries a more meaningful goodwill and JGAAP amortization burden; relative to more highly levered consolidators, its debt/EBITDA and interest coverage remain favorable. The operational profile is therefore characterized by resilient service revenue and good cash generation, balanced against margin sensitivity, acquisition-accounting drag and low current reinvestment.